Ozarelix

Drug Profile

Ozarelix

Alternative Names: D-63153; SPI-153

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Spectrum Pharmaceuticals
  • Class Antineoplastics; Peptides
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer
  • Preclinical Endometriosis
  • Discontinued Alzheimer's disease; Benign prostatic hyperplasia

Most Recent Events

  • 11 Jun 2015 Phase-II development for prostate cancer is ongoing in the US and India
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc
  • 14 Aug 2012 Spectrum Pharmaceuticals initiates enrolment in an expanded phase IIb trial for Prostate cancer in USA and India (NCT01252693)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top